[{"orgOrder":0,"company":"Abvance Therapeutics","sponsor":"Helmsley Charitable Trust","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Insulin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Abvance Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Abvance Therapeutics \/ Helmsley Charitable Trust","highestDevelopmentStatusID":"14","companyTruncated":"Abvance Therapeutics \/ Helmsley Charitable Trust"}]

Find Clinical Drug Pipeline Developments & Deals by Abvance Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The funding will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate developing to treat diabetes.

                          Brand Name : ABV100

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          September 10, 2024

                          Lead Product(s) : Insulin,Glucagon

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Helmsley Charitable Trust

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank